Eli Lilly Reports Positive Results for Retevmo in NSCLC Trial
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Feb 16 2026
0mins
Should l Buy LLY?
Source: PRnewswire
- Trial Success: The LIBRETTO-432 trial demonstrated that Retevmo (selpercatinib) as adjuvant therapy significantly improved event-free survival (EFS) in early-stage RET fusion-positive non-small cell lung cancer (NSCLC) patients, indicating its potential value and likely enhancing market acceptance.
- Survival Trends Favorable: Although overall survival results were immature at the time of analysis, preliminary data showed a favorable trend for Retevmo, highlighting its importance in early treatment and potentially encouraging more patients to undergo genomic testing for optimized therapy.
- Patient Recruitment: The LIBRETTO-432 trial enrolled 151 patients randomized 1:1 to receive either Retevmo or placebo, ensuring the reliability and clinical applicability of the results, further validating the use of targeted therapies in lung cancer.
- Future Outlook: Eli Lilly plans to present detailed trial results at an upcoming medical congress and submit data to global health authorities, which is expected to accelerate the adoption of targeted therapies in early-stage NSCLC patients and promote the widespread use of genomic testing.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy LLY?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on LLY
Wall Street analysts forecast LLY stock price to rise
20 Analyst Rating
18 Buy
2 Hold
0 Sell
Strong Buy
Current: 989.870
Low
950.00
Averages
1192
High
1500
Current: 989.870
Low
950.00
Averages
1192
High
1500
About LLY
Eli Lilly and Company is a medicine company, which discovers, develops, manufactures, and market products in a single business segment called human pharmaceutical products. The Company manufacture and distribute its products through facilities in the United States, including Puerto Rico, and in Europe and Asia. The Company’s products are sold in approximately 90 countries. Its Cardiometabolic Health products Basaglar; Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, and others; Humulin, Humulin 70/30, and others; Jardiance; Mounjaro; Trulicity; Zepbound, and others. Its oncology products include Cyramza, Erbitux, Tyvyt, Verzenio, Retevmo, Jaypirca, and others. Its immunology products include Ebglyss, Olumiant, Omvoh, and Taltz. Its neuroscience products include Emgality and Kisunla. Its LillyDirect, a direct-to-patient digital health care platform, provides delivery of select Lilly medicines dispensed by third-party pharmacies to patients.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Roche Secures CE Mark for Alzheimer's Blood Test
- CE Mark Approval: Swiss pharmaceutical company Roche announced that its second Elecsys blood test for Alzheimer's disease has received CE mark approval, allowing it to sell in the region and further expand its market share in the neuroscience sector.
- Collaborative Development: The test was developed in partnership with U.S. company Eli Lilly, highlighting the ongoing collaboration between the two firms in the early diagnosis of Alzheimer's disease, which is expected to enhance market acceptance and clinical application of related products.
- Market Potential: With the global increase in Alzheimer's disease patients, the new testing tool will aid in early identification and intervention, thereby improving patient quality of life and alleviating the burden on healthcare systems, presenting significant social and economic implications.
- Strategic Importance: Securing CE mark not only strengthens Roche's competitive position in the Alzheimer's field but also lays the groundwork for future innovative product launches in the European market, reflecting the company's long-term commitment to the neuroscience domain.
See More
Eli Lilly Launches Alzheimer's Drug Lormalzi in India
- Drug Launch: U.S.-based Eli Lilly launched its Alzheimer's drug Lormalzi, also known as Donanemab, in India on Wednesday, marking a significant step in the company's global market expansion and addressing the growing demand for Alzheimer's treatments among India's aging population.
- Market Potential: With over 8 million Alzheimer's patients in India, the introduction of Lormalzi is expected to not only improve patients' quality of life but also potentially generate substantial market share and revenue growth for Eli Lilly, further solidifying its position in the global pharmaceutical industry.
- Pricing Strategy: While specific pricing details have yet to be announced, based on the current exchange rate (1 USD = 95.76 INR), Eli Lilly may adopt a competitive pricing strategy to attract more patients and enhance drug accessibility, thereby increasing market penetration.
- R&D Investment: The launch of this new drug reflects Eli Lilly's ongoing investment in Alzheimer's research and development, indicating the company's commitment to addressing the challenges posed by a global aging society through innovative therapies, which will further drive its long-term growth strategy.
See More
Eli Lilly Reports Positive Results for Lower Dose Zepbound and Foundayo
- Positive Trial Results: Eli Lilly's late-phase trials indicate that lower doses of Zepbound and the oral drug Foundayo effectively help patients maintain weight loss, addressing a significant unmet need in obesity treatment by preventing weight regain.
- SURMOUNT-MAINTAIN Trial: In the 112-week trial, patients on the maximum tolerated dose maintained nearly all their weight loss, while those stepping down to 5 mg regained only an average of 5.6 kg, demonstrating the drugs' efficacy and safety.
- ATTAIN-MAINTAIN Trial: In the 52-week trial, patients switching from higher-dose Zepbound or Wegovy to Foundayo maintained only 0.9 kg and 5.0 kg of their prior weight loss, preserving 78% to 82% of their weight loss, further validating the clinical value of the drugs.
- Good Safety Profile: Both trials reported low discontinuation rates due to adverse events, under 8% for Foundayo and under 1% for Zepbound, indicating that their safety profiles are consistent with earlier studies and boosting market confidence in these therapies.
See More
Eli Lilly's New Drug Trials Show Long-Term Weight Loss Maintenance
- Long-Term Weight Maintenance: In the ATTAIN-MAINTAIN trial, participants switching from Wegovy to Foundayo maintained an average weight loss of 0.9 kg, demonstrating the drug's effectiveness in long-term weight management, potentially offering a sustainable treatment option for obesity patients.
- Zepbound's Efficacy: The SURMOUNT-MAINTAIN trial showed Zepbound's strong performance in weight maintenance, with participants preserving an average weight loss of 25.2 kg after 60 weeks, highlighting its significance and potential demand in obesity treatment.
- Safety Profile Analysis: Both trials indicated that Foundayo and Zepbound exhibited safety profiles consistent with prior Phase 3 studies, with common adverse events including nausea and diarrhea, ensuring patient safety and tolerability during treatment.
- Broad Market Potential: Eli Lilly's commitment to providing multiple treatment options for obesity patients is reinforced by the results from ATTAIN-MAINTAIN and SURMOUNT-MAINTAIN, which will drive further development in the obesity treatment market to meet the demand for long-term weight management solutions.
See More
Eli Lilly Reports Significant Findings on Weight Maintenance with New Drugs
- Long-term Weight Maintenance: In the ATTAIN-MAINTAIN trial, participants switching from Wegovy to Foundayo maintained an average weight gain of only 0.9 kg, demonstrating the drug's effectiveness in weight maintenance and reinforcing Eli Lilly's market position in obesity treatment.
- Zepbound's Efficacy: Results from the SURMOUNT-MAINTAIN trial showed that participants maintained all weight loss after 60 weeks of treatment with Zepbound, with those continuing on Zepbound MTD averaging a 25.2 kg weight loss at week 112, indicating its potential for long-term weight management.
- Consistent Safety Data: Both trials reported safety profiles for Foundayo and Zepbound consistent with previous Phase 3 studies, with common adverse events including nausea and diarrhea, enhancing physician confidence in prescribing these medications in clinical practice.
- Broad Market Prospects: Eli Lilly's commitment to providing multiple treatment options, coupled with the positive results from ATTAIN-MAINTAIN and SURMOUNT-MAINTAIN, will aid the company's expansion in the obesity drug market, addressing patient needs for long-term treatment solutions.
See More
UBS Sees 50% Upside for MBX Biosciences Stock
- Stock Potential: MBX Biosciences has surged over 230% in the past year, and UBS analysts project a further 50% upside with a price target of $60, reflecting strong market confidence in the company's prospects.
- Positive Clinical Data: UBS reports that MBX's GLP-1 treatment shows promising results in early proof of concept, particularly excelling in efficacy and tolerability, which are crucial for attracting both investors and patients.
- Expansive Market Outlook: The global market for type-2 diabetes and obesity treatments is expected to reach $190 billion by 2035, positioning MBX favorably in this rapidly growing sector, potentially driving further stock appreciation.
- Analyst Consensus: Among the 11 analysts covering MBX, 10 have rated it as a buy or strong buy, indicating widespread market confidence in MBX's future developments and reinforcing its competitive position in the biotech industry.
See More
Roche Secures CE Mark for Alzheimer's Blood Test
- CE Mark Approval: Swiss pharmaceutical company Roche announced that its second Elecsys blood test for Alzheimer's disease has received CE mark approval, allowing it to sell in the region and further expand its market share in the neuroscience sector.
- Collaborative Development: The test was developed in partnership with U.S. company Eli Lilly, highlighting the ongoing collaboration between the two firms in the early diagnosis of Alzheimer's disease, which is expected to enhance market acceptance and clinical application of related products.
- Market Potential: With the global increase in Alzheimer's disease patients, the new testing tool will aid in early identification and intervention, thereby improving patient quality of life and alleviating the burden on healthcare systems, presenting significant social and economic implications.
- Strategic Importance: Securing CE mark not only strengthens Roche's competitive position in the Alzheimer's field but also lays the groundwork for future innovative product launches in the European market, reflecting the company's long-term commitment to the neuroscience domain.
See More
Eli Lilly Launches Alzheimer's Drug Lormalzi in India
- Drug Launch: U.S.-based Eli Lilly launched its Alzheimer's drug Lormalzi, also known as Donanemab, in India on Wednesday, marking a significant step in the company's global market expansion and addressing the growing demand for Alzheimer's treatments among India's aging population.
- Market Potential: With over 8 million Alzheimer's patients in India, the introduction of Lormalzi is expected to not only improve patients' quality of life but also potentially generate substantial market share and revenue growth for Eli Lilly, further solidifying its position in the global pharmaceutical industry.
- Pricing Strategy: While specific pricing details have yet to be announced, based on the current exchange rate (1 USD = 95.76 INR), Eli Lilly may adopt a competitive pricing strategy to attract more patients and enhance drug accessibility, thereby increasing market penetration.
- R&D Investment: The launch of this new drug reflects Eli Lilly's ongoing investment in Alzheimer's research and development, indicating the company's commitment to addressing the challenges posed by a global aging society through innovative therapies, which will further drive its long-term growth strategy.
See More
Eli Lilly Reports Positive Results for Lower Dose Zepbound and Foundayo
- Positive Trial Results: Eli Lilly's late-phase trials indicate that lower doses of Zepbound and the oral drug Foundayo effectively help patients maintain weight loss, addressing a significant unmet need in obesity treatment by preventing weight regain.
- SURMOUNT-MAINTAIN Trial: In the 112-week trial, patients on the maximum tolerated dose maintained nearly all their weight loss, while those stepping down to 5 mg regained only an average of 5.6 kg, demonstrating the drugs' efficacy and safety.
- ATTAIN-MAINTAIN Trial: In the 52-week trial, patients switching from higher-dose Zepbound or Wegovy to Foundayo maintained only 0.9 kg and 5.0 kg of their prior weight loss, preserving 78% to 82% of their weight loss, further validating the clinical value of the drugs.
- Good Safety Profile: Both trials reported low discontinuation rates due to adverse events, under 8% for Foundayo and under 1% for Zepbound, indicating that their safety profiles are consistent with earlier studies and boosting market confidence in these therapies.
See More
Eli Lilly's New Drug Trials Show Long-Term Weight Loss Maintenance
- Long-Term Weight Maintenance: In the ATTAIN-MAINTAIN trial, participants switching from Wegovy to Foundayo maintained an average weight loss of 0.9 kg, demonstrating the drug's effectiveness in long-term weight management, potentially offering a sustainable treatment option for obesity patients.
- Zepbound's Efficacy: The SURMOUNT-MAINTAIN trial showed Zepbound's strong performance in weight maintenance, with participants preserving an average weight loss of 25.2 kg after 60 weeks, highlighting its significance and potential demand in obesity treatment.
- Safety Profile Analysis: Both trials indicated that Foundayo and Zepbound exhibited safety profiles consistent with prior Phase 3 studies, with common adverse events including nausea and diarrhea, ensuring patient safety and tolerability during treatment.
- Broad Market Potential: Eli Lilly's commitment to providing multiple treatment options for obesity patients is reinforced by the results from ATTAIN-MAINTAIN and SURMOUNT-MAINTAIN, which will drive further development in the obesity treatment market to meet the demand for long-term weight management solutions.
See More
Eli Lilly Reports Significant Findings on Weight Maintenance with New Drugs
- Long-term Weight Maintenance: In the ATTAIN-MAINTAIN trial, participants switching from Wegovy to Foundayo maintained an average weight gain of only 0.9 kg, demonstrating the drug's effectiveness in weight maintenance and reinforcing Eli Lilly's market position in obesity treatment.
- Zepbound's Efficacy: Results from the SURMOUNT-MAINTAIN trial showed that participants maintained all weight loss after 60 weeks of treatment with Zepbound, with those continuing on Zepbound MTD averaging a 25.2 kg weight loss at week 112, indicating its potential for long-term weight management.
- Consistent Safety Data: Both trials reported safety profiles for Foundayo and Zepbound consistent with previous Phase 3 studies, with common adverse events including nausea and diarrhea, enhancing physician confidence in prescribing these medications in clinical practice.
- Broad Market Prospects: Eli Lilly's commitment to providing multiple treatment options, coupled with the positive results from ATTAIN-MAINTAIN and SURMOUNT-MAINTAIN, will aid the company's expansion in the obesity drug market, addressing patient needs for long-term treatment solutions.
See More
UBS Sees 50% Upside for MBX Biosciences Stock
- Stock Potential: MBX Biosciences has surged over 230% in the past year, and UBS analysts project a further 50% upside with a price target of $60, reflecting strong market confidence in the company's prospects.
- Positive Clinical Data: UBS reports that MBX's GLP-1 treatment shows promising results in early proof of concept, particularly excelling in efficacy and tolerability, which are crucial for attracting both investors and patients.
- Expansive Market Outlook: The global market for type-2 diabetes and obesity treatments is expected to reach $190 billion by 2035, positioning MBX favorably in this rapidly growing sector, potentially driving further stock appreciation.
- Analyst Consensus: Among the 11 analysts covering MBX, 10 have rated it as a buy or strong buy, indicating widespread market confidence in MBX's future developments and reinforcing its competitive position in the biotech industry.
See More
